Results 21 to 30 of about 1,327 (120)

Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study

Cancer Medicine, 2023
Background Epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) develops resistance to tyrosine kinase inhibitors (TKIs).
Chunhong Hu, Sixuan Wu, Renfang Deng, Yuanqiang Wu, Yue Pan, Long Shu, Fang Wu   +6 more
doaj   +1 more source

Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors

Frontiers in Oncology, 2021
AimTo evaluate the clinical outcomes of metastatic colorectal cancer (mCRC) patients with oligometastases, oligoprogression, or local control of dominant tumors after stereotactic body radiotherapy (SBRT) and establish a nomogram model to predict the ...
Xiaoqin Ji, Yulu Zhao, Xixu Zhu, Zetian Shen, Aomei Li, Cheng Chen, Xiaoyuan Chu   +6 more
doaj   +1 more source

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC

Therapeutic Advances in Medical Oncology, 2023
Background: Oligoprogressive disease is recognized as the overall umbrella term; however, a small number of progressions on imaging can represent different clinical scenarios. This study aims to explore the optimal treatment strategy after immunotherapy (
Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li, Shun Lu   +5 more
doaj   +1 more source

Stereotactic Radiation for Oligometastatic and Oligoprogressive Stage IV Breast Cancer: A Case-Based Review

Current Oncology, 2023
For decades, the distant progression of breast cancer has been the purview of systemic therapy alone or with low to moderate-dose radiation therapy intended for the palliation of symptomatic metastases.
Gary M. Freedman, Joshua A. Jones, Neil K. Taunk   +2 more
doaj   +1 more source

The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review

Current Oncology, 2023
Stereotactic body radiotherapy (SBRT) has emerged as a technique to treat oligoprogressive sites among patients with breast cancer who are otherwise doing well on systemic therapy. This study systematically reviewed the efficacy and safety of SBRT in the
Bernie Yan, Sherif Ramadan, Katarzyna J. Jerzak, Alexander V. Louie, Elysia Donovan   +4 more
doaj   +1 more source

Successful treatment of induced oligometastasis and repeated oligoprogression of advanced lung adenocarcinoma with immunotherapy and radiotherapy

Thoracic Cancer, 2022
Highly active and durable systemic therapies such as targeted therapy and immunotherapy can convert widespread metastatic disease into oligometastatic status, for which metastasis‐directed local intervention can control and potentially prolong survival ...
Ho Young Lee, Sung Hyun Kim, Hong Yeul Lee, Young‐Min Lee, Ji Yeon Han, Heunglae Cho, Hyun‐Kyung Lee   +6 more
doaj   +1 more source

Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma

Current Oncology, 2023
Stereotactic ablative radiotherapy (SABR) has challenged the conventional wisdom surrounding the radioresistance of renal cell carcinoma (RCC). In the past decade, there has been a significant accumulation of clinical data to support the safety and ...
Rohit K. Raj, Rituraj Upadhyay, Shang-Jui Wang, Eric A. Singer, Shawn Dason   +4 more
doaj   +1 more source

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

Case Reports in Oncology, 2016
Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous non-small cell lung cancer (NSCLC). We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative ...
Shao-Lun Lu, Feng-Ming Hsu, Kuan-Yu Chen, Chao-Chi Ho, James Chih-Hsin  Yang, Jason Chia-Hsien Cheng   +5 more
doaj   +1 more source

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer

Frontiers in Oncology, 2020
Purpose/Objective: Oligometastatic disease (OMD) and oligoprogressive disease (OPD) describe tumor states with a limited metastasization. In contrast to other disease states, treatment of OMD or OPD has not yet become common for breast cancer.
Fabian Weykamp, Fabian Weykamp, Fabian Weykamp, Laila König, Laila König, Laila König, Katharina Seidensaal, Katharina Seidensaal, Katharina Seidensaal, Tobias Forster, Tobias Forster, Tobias Forster, Philipp Hoegen, Philipp Hoegen, Philipp Hoegen, Sati Akbaba, Sati Akbaba, Sati Akbaba, Stephan Mende, Stephan Mende, Stephan Mende, Stefan E. Welte, Stefan E. Welte, Stefan E. Welte, Thomas M. Deutsch, Andreas Schneeweiss, Jürgen Debus, Jürgen Debus, Jürgen Debus, Jürgen Debus, Jürgen Debus, Jürgen Debus, Juliane Hörner-Rieber, Juliane Hörner-Rieber, Juliane Hörner-Rieber, Juliane Hörner-Rieber   +35 more
doaj   +1 more source

Is Oligometastatic Cancer Curable? A Survey of Oncologist Perspectives, Decision Making, and Communication

Advances in Radiation Oncology, 2023
Purpose: Oligometastatic disease (OMD) refers to a limited state of metastatic cancer, which potentially derives benefit from local treatments. Given the relative novelty of this paradigm, oncologist perspectives on OMD are not well established.
Hae Lin Cho, BA, Tracy Balboni, MD, Sebastian Matthias Christ, MD, PhD, Brandon Turner, MD, MSc, Alexander Spektor, MD, PhD, Subha Perni, MD   +5 more
doaj   +1 more source